you can contact us

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Jump to Contact Form

Corporate information

Lantheus

201 Burlington Road
South Building
Bedford, MA 01730

Phone: 1-800-362-2668

Email: info@lantheus.com

Customer service

US Customer Service/Order TruVu

Phone: 1-800-964-0446

Hours: 8:00 am to 7:00 pm ET, Monday to Friday

Email: cspyl@lantheus.com

PYLARIFY TruVu reimbursement resources

Call toll-free: 844-339-8514

Email: reimbursement@lantheuslink.com

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding, and payment information.

Adverse events and product quality complaint reports

Adverse events and product quality complaint reports must be reported through the following channels:

Phone: 1-800-343-7851
Press Option 2 for adverse events
Press Option 2 for product quality complaints
Fax: 978-436-7296
Email: lantheussafety@lantheus.com

Contact Form

*Please complete the required fields below.

*I am interested in the following (check all that apply):

Email adverse events and product quality complaints to: lantheussafety@lantheus.com.

By submitting this form, you are granting Lantheus permission to process your personal information to send you additional information and promotional communications related to Lantheus products. You may opt out of these communications at any time by unsubscribing through the link in any email.

Lantheus respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Terms of Use and Privacy Policy.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

To report suspected adverse reactions for PYLARIFY TRUVU, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for PYLARIFY TRUVU.

INDICATION

PYLARIFY TRUVU (piflufolastat F 18) Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Image Misinterpretation

Imaging interpretation errors can occur with PYLARIFY TRUVU imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY TRUVU for imaging biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY TRUVU for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY TRUVU uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended.

Hypersensitivity Reactions

Monitor patients for hypersensitivity reactions, particularly those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.

Radiation Risks

PYLARIFY TRUVU exposes patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

Adverse Reactions

The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions.

Drug Interactions

Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY TRUVU in prostate cancer. The effect of these therapies on performance of PYLARIFY TRUVU PET has not been established.

To report suspected adverse reactions for PYLARIFY TRUVU, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for PYLARIFY TRUVU.